CORCEPT THERAPEUTICS UK LIMITED
Company Information
Registered Address
Eastcastle House27/28 Eastcastle Street London W1W 8DH
Company Size
201-1000 employees
Founded
1998
Categories
Manufacture of basic pharmaceutical productsResearch and experimental development on biotechnology
Visa Information
Licensed Visa Types
skilled worker
First Recorded as Sponsor
December 4, 2024
Annual Issuance Trend
Suggest an edit
Claim this company
Jobs (~3 days delayed) in Remote
You're seeing delayed jobs. Sign up free to unlock fresh jobs.
Associate Director, Field Reimbursement LeadCORCEPT THERAPEUTICS UK LIMITED
Corcept is leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators. In 2012, we received FDA approval of Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat seriou
3/30/2026
Senior Director, National Field Access, EndocrinologyCORCEPT THERAPEUTICS UK LIMITED
Corcept is leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators. In 2012, we received FDA approval of Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat seriou
3/30/2026
Senior Regional Clinical Research AssociateCORCEPT THERAPEUTICS UK LIMITED
Corcept is leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators. In 2012, we received FDA approval of Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat seriou
3/30/2026
Medical Science Liaison, Endocrinology – Mid-Atlantic RegionCORCEPT THERAPEUTICS UK LIMITED
Corcept is leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators. In 2012, we received FDA approval of Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat seriou
3/30/2026
You've reached the end!
No more jobs to load.